A European Academy of Dermatology and Venereology study explored the pathway from dermatologic consult to diagnosis to treatment and outcomes in the health care system.
A version of this article was originally published by Dermatology Times. This version has been lightly edited.
A study recently published in Journal of the European Academy of Dermatology and Venereology sought to examine the relationship between patients and their respective journeys through the dermatology and health care systems.1 The study, closely looking at a cohort of patients spanning 27 European countries, found that 30.3% of patients reported receiving a dermatology consult within the previous 2 years.
Between November 10, 2020, and August 5, 2021, investigators conducted the multinational, cross-sectional study using a framework from the European Academy of Dermatology and Venereology’s “Burden of Skin Diseases in Europe” study.2 They noted that research and data closely examining the dermatology patient journey have been limited and scarce.
Participants (n = 44,689) were adult patients from 24 European Union (EU) and 3 non-EU countries (Norway, Switzerland, and the United Kingdom). Upon completing a multimodule questionnaire inquiring about patients’ dermatologic histories, diagnosed skin conditions, and additional and/or unpleasant skin sensations, the researchers gathered information related to the demographics, clinical outcomes, and health care of all patients. In cases of patients experiencing multiple or overlapping skin conditions, the investigators asked participants to respond in accordance with their most bothersome skin concern.
During the 12 months leading up to the study, approximately 43.4% reported having at least 1 skin condition or disease, excluding skin or mole checks. In estimating dermatologic visits prior to study inclusion, half of the participants reported visiting a dermatologist in the previous 5 years. This number steadily decreased over time, with 30.3% of participants reporting a visit within the most recent 2 years and 18.4% receiving a dermatologic consultation in the most recent 12 months.
Approximately 33.1% of participants admitted to having never received a dermatologic consultation.
The most common reasons for visiting dermatologists and receiving a dermatologic consultation included mole and skin checks (22.3%), recurrent or long-lasting skin disease (16.2%), and acute or transient skin problems (12.0%).
In order of prevalence, the most commonly self-reported skin conditions among participants were fungal skin infections, alopecia, acne, and atopic dermatitis or eczema. The least common self-reported skin conditions included rosacea and skin cancer. Participants also reported diagnoses of psoriasis and sexually transmitted diseases (STD) affecting their skin.
Investigators also explored the reasons for not consulting dermatologic professionals by diagnosed skin condition. Most commonly, patients with alopecia, acne, and fungal skin infections did not consult dermatologists. More than half of the patients with alopecia (53.7%) reported that they felt their condition was not worrisome enough to consult a health care provider, and 39.7% of patients with psoriasis had already consulted a dermatologist and felt they knew how to best manage their condition on their own. Patients with acne, atopic dermatitis, fungal infections, rosacea, or STDs most commonly felt their condition was manageable either on their own or with the support of loved ones.
A key limitation of this study, according to the study authors, was the method of self-reporting used to collect data. However, the investigators felt the nature of this data collection was crucial to obtaining data more representative of the general population.
"Mapping patient journeys may provide important insight into the value of health care services,” the study authors wrote. “Based on patients' experiences, providers can address the needs of the patient with targeted interventions. Streamlining the patient journey by providing guidelines for primary and secondary care across specialisms can improve patients' outcomes and reduce diagnostic delay and health care expenses.”
References
1. Richard MA, Paul C, Nijsten T, et al. The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study. J Eur Acad Dermatol Venereol. 2023;37(7 suppl):17-24. doi:10.1111/jdv.18916
2. McGrath BM, Hughes O. The dermatology patient journey from initial consultation to diagnosis. J Eur Acad Dermatol Venereol. 2023;37(7 suppl):25-26. doi:10.1111/jdv.18987
Despite Record ACA Enrollment, Report Reveals Underinsured Americans are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access and affordability to health care.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More